Table 3.
Circulating tumor cells (CTCs), KRAS status of the tumor, KRAS status in the CTCs as determined by multiplex assay and serum tumor markers. Sex, F (Female) M (Male). Type, Col. Colon adenocarcinoma; Rec, Rectal adenocarcinoma. Stage, Tumor stage according to UICC.
| Patient | Sex | Tumor | CTCs/CTMs | Tumoral markers | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Type | Stage | KRAS genotype | Cytology | CTCs | CTMs | Multiplex KRAS | ACE (μg/L) | CA199 (kU/L) | ||
| 3 | M | Col. | IV | WTa | + | 2 | 0 | − | 19.9 | 12.3 |
| 4 | F | Rec. | IIIb | WTa | + | 1 | 0 | − | 2.7 | 23.4 |
| 5 | M | Col. | IIIb | WTa | + | 7 | 0 | + | 1.8 | 13.1 |
| 6 | F | Col. | IIIb | c.35G > A (G12D)a | + | 15 | 0 | + | 1.9 | 15.8 |
| 7 | M | Col. | IIIc | WTa | + | 9 | 0 | − | 6.8 | <1.2 |
| 8 | M | Col. | IV | WTa | + | 25 | 30 | Failed | 1.4 | <1.2 |
| 9 | F | Col. | IIIb | WTa | + | 16 | 0 | − | 20.1 | 20.5 |
| 11 | M | Col. | I | c.38G > A (G13D)a | + | 2 | 0 | − | 2.4 | 15.6 |
| 12 | F | Col. | I | WTa | + | 2 | 0 | − | 7.6 | 17.3 |
| 13 | M | Col. | I | na | − | 0 | 0 | − | 1.1 | 7.1 |
| 14 | M | Col. | IIb | c.34G > A (G12S)b | na | na | na | + | 3.9 | <1.2 |
| 15 | F | Rec. | IIa | WTa | na | na | na | − | 0.4 | 32.5 |
| 17 | M | Col. | IIIb | Mutc | na | na | na | + | 0.6 | 8.9 |
| 18 | F | Col. | IIIb | WTc | na | na | na | − | 1.6 | 41.4 |
| 19 | M | Col. | is | c.38G > A (G13D)a | + | 2 | 1 | + | 1 | 12.7 |
| 20 | M | Rec. | I | WTc | na | na | na | − | 1.6 | 11 |
| 21 | F | Col. | IIa | c.35G > T (G12V)a | na | na | na | + | 11 | 5.7 |
| 22 | F | Col. | IIa | c.38G > A (G13D)a | + | 1 | 0 | + | 68.2 | 813.2 |
| 23 | M | Rec. | IIa | WTc | + | 10 | 0 | + | 1.8 | 18.1 |
| 24 | M | Col. | IIIb | c.38G > A (G13D)b | + | 1 | 0 | + | 1.8 | 42.8 |
| 26 | F | Col. | IV | c.35G > A (G12D)b | + | 2 | 0 | + | 26.5 | 4781 |
| 30 | M | Col. | is | na | + | 12 | 0 | + | 1.2 | 45.6 |
| 31 | F | Col. | IIa | WTb | + | 2 | 0 | + | 2.6 | 40.8 |
| 32 | F | Col. | IIIc | WTa | + | 1 | 0 | − | 1.3 | 12.5 |
| 33 | M | Rec. | I | na | − | 0 | 0 | + | 3.7 | 14.3 |
| 34 | F | Col. | IIIa | c.35G > A (G12D)a | + | 7 | 0 | + | 0.8 | 13 |
| 35 | F | Col. | IIa | WTa | + | 4 | 0 | Failed | 1.6 | 16 |
| 36 | M | Col. | IV | WTb | + | 3 | 0 | Failed | 36.8 | 990.6 |
| 37 | M | Col. | IIIb | c.38G > A (G13D)a | + | 3 | 0 | − | 1.6 | 38.3 |
| 38 | F | Rec. | IIIb | WTa | + | 1 | 0 | − | 0.3 | 6.4 |
| 39 | M | Col. | IIIa | WTa | + | 4 | 0 | + | 1.4 | 17 |
| 40 | M | Col. | IIa | WTa | + | 5 | 0 | Failed | 1.6 | 66.7 |
| 41 | F | Rec. | is | na | − | 0 | 0 | + | 0.5 | 3.5 |
| 42 | M | Col. | I | WTc | + | 10 | 0 | Failed | 2.4 | 5.6 |
| 43 | M | Col. | IIa | c.34G > T (G12C)a | + | 3 | 0 | + | 1.3 | 13.8 |
Tumor KRAS genotype as determined by a) tumor genotyping with MiSeq Illumina Tumor, b) HRM + Sanger sequencing or c) HRM only. Cytology, +, the number of circulating tumor cells was at least 1 CTCs per 3 mL whole blood. CTCs, number of circulating tumor cells per 3 mL whole blood. CTMs, number of circulating microemboli per 3 mL whole blood. The multiplex assay screen the 7 most frequent mutations in KRAS codons 12–13. The test is considered positive if the measured abundance ratio is >0.2% according to our validation specifications. Serum concentrations of the tumoral markers CEA and CA19.9 are indicated (normal CEA < 5 μg/L and CA19.9 37 kU/L). In Tumor KRAS genotype column a, b, c refers to the method used for genotyping Illumina, HRM + Sanger Sequencing or digital PCR, respectively. na: not available.